Scancell Holdings Share News (SCLP)

Scancell said it had received a patent for its DNA ImmunoBody treatment in Australia. Australia is the first jurisdiction to approve the DNA patent. Scancell said it was an important step to comprehensively protecting the technology.Scancell specialises in treatments to encourage the immune system to treat or prevent cancer. The patent granted in Australia covers the DNA ImmunoBody technology and is important for the protection of all the company's ImmunoBody vaccines, Scancell said. It has also been filed in the US, Europe and other major markets. Richard Goodfellow, Joint Chief Executive of Scancell, said: "Our lead ImmunoBody for melanoma, SCIB1, currently in Phase I/II clinical trials, is based on the DNA approach. The approval of this DNA patent is therefore a very important step in the development and commercialisation of our ImmunoBody platform."The composition-of-matter patent for SCIB1, Scancell's ImmunoBody vaccine for melanoma has been granted in Europe, Turkey and South Africa. Scancell's protein ImmunoBody patent has been approved in the US, Europe, Japan and Australia.